Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

paroxetine

Drug and asset intelligence for paroxetine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Sponsor company

GSK →

Recent signals(1)

ClinicalJune 10, 2026

Study Compares PE Therapy, Pharmacotherapy, and Combination for PTSD in Veterans

A randomized trial will compare the effectiveness of Prolonged Exposure therapy, paroxetine, venlafaxine, and their combination in veterans with PTSD.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

GSK — Paroxetine

Monitor the trial's progress, particularly the mid and post-treatment assessments at 7 and 14 weeks, for insights into treatment efficacy.

June 10, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Psychiatry →
PTSD →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.